These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 8420182

  • 1. IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome.
    Oertel WH, Schwarz J, Tatsch K, Arnold G, Gasser T, Kirsch CM.
    Adv Neurol; 1993; 60():519-24. PubMed ID: 8420182
    [Abstract] [Full Text] [Related]

  • 2. IBZM-SPECT imaging in Parkinson's disease. Quantification of binding ratios from sequential SPECT measurements in patients and controls.
    Cordes M, Hierholzer J, Schelosky L, Poewe W, Cordes I, Horowski R, Eichstaedt H, Schmidt D, Felix R.
    Adv Neurol; 1993; 60():525-8. PubMed ID: 8420183
    [No Abstract] [Full Text] [Related]

  • 3. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.
    Schwarz J, Tatsch K, Gasser T, Arnold G, Oertel WH.
    Mov Disord; 1997 Nov; 12(6):898-902. PubMed ID: 9399212
    [Abstract] [Full Text] [Related]

  • 4. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT.
    Schelosky L, Hierholzer J, Wissel J, Cordes M, Poewe W.
    Mov Disord; 1993 Oct; 8(4):453-8. PubMed ID: 8232354
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa.
    Schwarz J, Oertel WH, Tatsch K.
    J Nucl Med; 1996 Jul; 37(7):1112-5. PubMed ID: 8965179
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Cerebral SPECT with iodine-123 IBZM in patients with extrapyramidal system disorders: the evaluation of its sensitivity in therapy with dopaminergic drugs].
    Hierholzer J, Castelli L, Cordes M, Schelosky L, Poewe W, Felix R.
    Radiol Med; 1996 Mar; 91(3):207-10. PubMed ID: 8628932
    [Abstract] [Full Text] [Related]

  • 13. Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study.
    Pizzolato G, Chierichetti F, Rossato A, Cagnin A, Fabbri M, Dam M, Ferlin G, Battistin L.
    J Neural Transm Suppl; 1995 Mar; 45():113-22. PubMed ID: 8748616
    [Abstract] [Full Text] [Related]

  • 14. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
    Hierholzer J, Cordes M, Schelosky L, Barzen G, Poewe W, Henkes H, Keske U, Horowski R, Felix R.
    Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.